Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion.
about
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approachTeriflunomide for multiple sclerosisTeriflunomide for multiple sclerosisTeriflunomide for multiple sclerosisThe active metabolite of leflunomide, A77 1726, interferes with dendritic cell functionTargeting CD8 T-Cell Metabolism in TransplantationFingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapyCurrent and emerging therapies in multiple sclerosis: a systematic reviewEmerging therapies in multiple sclerosis.Immunomodulatory drugs and their application to the management of canine immune-mediated disease.T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tabletsRisk stratification and mitigation multiple sclerosis.Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects.Amelioration of experimental autoimmune uveitis by leflunomide in Lewis rats.Emerging therapies for treatment of multiple sclerosisExperimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?Role of oral teriflunomide in the management of multiple sclerosis.An update of teriflunomide for treatment of multiple sclerosis.Review of teriflunomide and its potential in the treatment of multiple sclerosis.Teriflunomide.Teriflunomide and its mechanism of action in multiple sclerosis.Back to the future for multiple sclerosis therapy: focus on current and emerging disease-modifying therapeutic strategies.The role of natural killer cells in multiple sclerosis and their therapeutic implications.Drugs in development for relapsing multiple sclerosis.Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.Recent advances in the treatment of multiple sclerosis.Myeloid cells - targets of medication in multiple sclerosis.From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.Multiple Sclerosis: Immunopathology and Treatment Update.Teriflunomide for oral therapy in multiple sclerosis.Immunosuppressive effects and mechanisms of leflunomide in dengue virus infection of human dendritic cells.In vitro evaluation of physiologically relevant concentrations of teriflunomide on activation and proliferation of primary rodent microglia.Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis.Unveiling some FDA-approved drugs as inhibitors of the store-operated Ca2+ entry pathway.Immunotherapy of multiple sclerosis.Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with leflunomide.
P2860
Q22305854-49DC8A72-A3A2-4107-ADB5-15D452A548ACQ24186016-ECC16401-0F15-4F0E-9D57-4CF18405C21BQ24198146-B9DC7C86-C749-4D78-BF7E-1AA896BDE68DQ24202177-128938BF-BEAC-47B1-88EC-E7DE0BB1453AQ24816880-4AD8F05D-B35B-4DEA-9B96-5A026BB770C2Q26777941-8C707D73-9640-411B-B976-C09F8BBEA344Q27011473-8A57B254-01D5-4E74-AACE-1CD2DDE5D278Q29010983-F826CBBA-C910-4C42-A7EA-0AE612ECAA3DQ31015100-DE21252D-F503-4D2E-9A85-CBDEC544E0CAQ33393823-399347AD-96F8-47BF-936F-800BD8A11153Q33723154-C2F2F8E5-1070-4987-9791-137D8188CAD8Q34066654-2A34A5B4-E748-4BF8-9CDE-C63456D8F85FQ34133316-EA509ED6-4D27-4397-B2A9-55CA66A01164Q34155446-00B51AE2-11BC-44DA-AC33-C70161CD9D83Q34389332-6CE62B00-CD61-4615-AB93-7AB5F37C4209Q34692643-CE533FCB-40D6-41D7-A532-DE316C0F54EDQ35557390-3F399E82-073F-4564-876E-3B41A77F6582Q35589934-2C90AE81-5B7A-4FB8-A33D-C690C30A5CC4Q36396476-A8FB3B9C-0066-4864-8C0F-AD40225DB393Q36803649-E1116E2E-C6A8-496F-8443-097A723AC15CQ36906008-C270325D-DB5E-41EA-A77B-6BD69C47D033Q37235715-3C604415-AB70-4CF5-9DF4-5AF05D465529Q37340103-08452350-2F9C-4400-9FC4-4EBC49E6FFEEQ37730005-8640D798-776F-4CA4-A59E-CF1E6FAB0CC1Q37773270-8F447F97-3EC8-497B-930A-01519CA0401DQ38089599-B769F3FD-6132-4DE2-ACBC-B86396F3D0A2Q38101004-296C4AD8-B2CB-4B7B-9D67-B0222A53E33BQ38107524-DDA53E3A-CC30-4B83-B9C4-7CB9CA11B3B8Q38117110-671C36D8-C06A-40F3-8898-A5293BA11531Q38836048-7FD9D27D-DFFE-4162-9FAE-A002F557641CQ38924828-AE3C4F13-0BCE-45AA-90EE-6007CCCB4F63Q39032639-B83D7697-899B-477E-892C-B4994B23CBFFQ39420793-9045CA48-57D8-4E82-8DD0-C14AC5CF1FC2Q39504360-F739A3E6-12BF-41AB-B49B-85FDCA7A6152Q40315102-2090332C-A4FA-41CC-8AFE-6B998B30FB26Q41167409-0552C3EB-AC16-4A58-92BB-1E2551BECF6CQ41877062-893E37D6-29D8-4B36-AB38-511F4CF1D00FQ42378965-D62DAFC9-9E2C-400A-BEF0-00D081B28AEAQ54502086-DD3C4A5D-2843-4AEF-AB23-E4AEB0C71E8BQ54536252-2986CCF7-BEDC-4B15-B013-DAC70E8E9587
P2860
Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Modulation of effector cell fu ...... ndent of pyrimidine depletion.
@en
Modulation of effector cell fu ...... ndent of pyrimidine depletion.
@nl
type
label
Modulation of effector cell fu ...... ndent of pyrimidine depletion.
@en
Modulation of effector cell fu ...... ndent of pyrimidine depletion.
@nl
prefLabel
Modulation of effector cell fu ...... ndent of pyrimidine depletion.
@en
Modulation of effector cell fu ...... ndent of pyrimidine depletion.
@nl
P2093
P2860
P356
P1476
Modulation of effector cell fu ...... ndent of pyrimidine depletion.
@en
P2093
Klaus Toyka
Stefan Jung
Tim Magnus
P2860
P304
P356
10.1189/JLB.0504308
P50
P577
2004-08-24T00:00:00Z